What is the appropriate dosing regimen for Ozempic (semaglutide)?

Ozempic (Semaglutide) Dosing Regimen

For type 2 diabetes, initiate Ozempic at 0.25 mg subcutaneously once weekly for 4 weeks, then increase to 0.5 mg weekly; if additional glycemic control is needed, escalate to 1 mg weekly after at least 4 weeks on the 0.5 mg dose. 1

Standard Dosing Protocol

For Glycemic Control in Type 2 Diabetes

Titration Schedule:

• Weeks 1-4: 0.25 mg subcutaneously once weekly 1, 2
• Week 5 onward: 0.5 mg once weekly 1, 2
• Optional escalation: After at least 4 weeks on 0.5 mg, may increase to 1.0 mg once weekly if additional glycemic control is required 1

The 0.25 mg starting dose is not therapeutic—it serves only to minimize gastrointestinal side effects during initiation 1, 2. The maintenance doses are 0.5 mg or 1.0 mg weekly 1.

For Weight Management (Obesity Indication)

When used specifically for weight management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, a higher dose regimen applies 1:

• Week 1-4: 0.25 mg once weekly 1
• Week 5-8: 0.5 mg once weekly 1
• Week 9-12: 1.0 mg once weekly 1
• Week 13-16: 1.7 mg once weekly 1
• Week 17 onward: 2.4 mg once weekly (maintenance dose) 1

Administration Details

• Route: Subcutaneous injection 1, 2
• Frequency: Once weekly, at any time of day, with or without meals 1
• Injection sites: Abdomen, thigh, or upper arm 2
• Needle compatibility: Use NovoFine® Plus or NovoFine® needles up to 8 mm length 2

Dose Adjustments for Special Populations

Renal Impairment

No dose adjustment required regardless of kidney function 1. This is a critical advantage—semaglutide can be used safely even in:

• eGFR 15-29 mL/min/1.73 m² 1
• eGFR <15 mL/min/1.73 m² 1
• End-stage renal disease 1

This contrasts sharply with other GLP-1 receptor agonists like exenatide and lixisenatide, which require dose adjustments or are contraindicated in advanced kidney disease 1.

Hepatic Impairment

No dose adjustment necessary 1

Flexible Titration for Improved Tolerability

Emerging evidence supports slower, more flexible titration to reduce gastrointestinal adverse events and improve adherence. A 2025 randomized trial demonstrated that starting at 0.0675 mg weekly (measured as five clicks on the dose selector) with gradual weekly increases of 0.0675 mg significantly reduced treatment discontinuation due to gastrointestinal side effects (2% vs 19% with standard titration, p=0.005) 3. Patients also experienced fewer days of nausea (2.88 vs 6.3 days, p=0.017) without compromising HbA1c or BMI outcomes 3.

Clinical judgment should guide titration speed based on individual tolerance—delays in dose escalation for gastrointestinal symptoms are appropriate 1.

Missed Dose Management

• If ≤2 consecutive doses missed: Resume at the same dose if previously well-tolerated; otherwise consider lowering the next dose 1
• If ≥3 consecutive doses missed: Consider restarting the titration schedule 1
• If a dose is missed, administer as soon as possible within 5 days; if >5 days have passed, skip the missed dose and resume the regular schedule 2

Higher Dose Option (2.0 mg)

For patients on 1.0 mg weekly who require additional glycemic control, semaglutide 2.0 mg once weekly is available 4. This higher dose demonstrated superior HbA1c reduction (-2.2% vs -1.9%, p=0.0003) and additional weight loss (-6.9 kg vs -6.0 kg, p=0.015) compared to 1.0 mg, with a similar safety profile 4.

Critical Safety Considerations

Gastrointestinal Effects

• Nausea, vomiting, and diarrhea are the most common adverse events, occurring in approximately 40%, 16%, and similar percentages respectively 1
• These effects are dose-dependent and typically transient, improving with gradual titration 1, 5
• Most gastrointestinal symptoms are mild-to-moderate 5

Contraindications

• Personal or family history of medullary thyroid carcinoma 1
• Multiple endocrine neoplasia syndrome type 2 (MEN2) 1
• History of serious hypersensitivity to semaglutide 1

Hypoglycemia Risk

When combined with insulin or sulfonylureas, reduce doses of these agents proactively to prevent hypoglycemia 1. Semaglutide alone carries minimal hypoglycemia risk due to glucose-dependent insulin secretion 1.

Drug Interactions

• Do not combine with other GLP-1 receptor agonists or DPP-4 inhibitors 1
• May delay gastric emptying, potentially affecting absorption of oral medications requiring rapid onset 1

Storage and Handling

• Unused pens: Refrigerate at 36°F-46°F (2°C-8°C) until expiration date 2
• In-use pens: May be stored at room temperature 59°F-86°F (15°C-30°C) or refrigerated for up to 56 days 2
• Do not freeze; discard if frozen 2
• Mark disposal date on calendar when first used 2